On March 14, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer, reported that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for an additional cancer detection technology patent (Press release, Anixa Biosciences, MAR 14, 2019, View Source [SID1234534316]). This patent provides broader coverage for the use of Anixa’s technology in a wider range of applications and protects critical new improvements developed for Anixa’s cancer detection technology. This patented technology is a key component of Cchek, Anixa’s early cancer detection platform that utilizes flow cytometry and artificial intelligence.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent is titled, "METHODS FOR USING ARTIFICIAL NEURAL NETWORK ANALYSIS ON FLOW CYTOMETRY DATA FOR CANCER DIAGNOSIS," and the inventors are Dr. Amit Kumar, John Roop, Anthony Campisi, and Dr. George Dominguez. This patent is assigned wholly to Anixa.

Dr. Amit Kumar, Anixa’s Chairman, President and CEO, stated, "We are pleased to receive further patent protection on our liquid biopsy technology. We plan to launch the first product utilizing this technology, a prostate cancer confirmatory test, in the third quarter of this year." Dr. Kumar continued, "Today, I will be presenting this technology including the latest data at the Molecular Medicine TriConference in San Francisco."